Literature DB >> 28263188

Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity.

Emanuela Teveroni, Marsha Pellegrino, Sabrina Sacconi, Patrizia Calandra, Isabella Cascino, Stefano Farioli-Vecchioli, Angela Puma, Matteo Garibaldi, Roberta Morosetti, Giorgio Tasca, Enzo Ricci, Carlo Pietro Trevisan, Giuliana Galluzzi, Alfredo Pontecorvi, Marco Crescenzi, Giancarlo Deidda, Fabiola Moretti.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder that is characterized by extreme variability in symptoms, with females being less severely affected than males and presenting a higher proportion of asymptomatic carriers. The sex-related factors involved in the disease are not known. Here, we have utilized myoblasts isolated from FSHD patients (FSHD myoblasts) to investigate the effect of estrogens on muscle properties. Our results demonstrated that estrogens counteract the differentiation impairment of FSHD myoblasts without affecting cell proliferation or survival. Estrogen effects are mediated by estrogen receptor β (ERβ), which reduces chromatin occupancy and transcriptional activity of double homeobox 4 (DUX4), a protein whose aberrant expression has been implicated in FSHD pathogenesis. During myoblast differentiation, we observed that the levels and activity of DUX4 increased progressively and were associated with its enhanced recruitment in the nucleus. ERβ interfered with this recruitment by relocalizing DUX4 in the cytoplasm. This work identifies estrogens as a potential disease modifier that underlie sex-related differences in FSHD by protecting against myoblast differentiation impairments in this disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28263188      PMCID: PMC5373881          DOI: 10.1172/JCI89401

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.

Authors:  Richard J L F Lemmers; Jelle J Goeman; Patrick J van der Vliet; Merlijn P van Nieuwenhuizen; Judit Balog; Marianne Vos-Versteeg; Pilar Camano; Maria Antonia Ramos Arroyo; Ivonne Jerico; Mark T Rogers; Daniel G Miller; Meena Upadhyaya; Jan J G M Verschuuren; Adolfo Lopez de Munain Arregui; Baziel G M van Engelen; George W Padberg; Sabrina Sacconi; Rabi Tawil; Stephen J Tapscott; Bert Bakker; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2014-09-25       Impact factor: 6.150

Review 2.  Facioscapulohumeral muscular dystrophy.

Authors:  Sabrina Sacconi; Leonardo Salviati; Claude Desnuelle
Journal:  Biochim Biophys Acta       Date:  2014-05-29

3.  Severe phenotype in infantile facioscapulohumeral muscular dystrophy.

Authors:  Lars Klinge; Michelle Eagle; Irene D Haggerty; Catherine E Roberts; Volker Straub; Kate M Bushby
Journal:  Neuromuscul Disord       Date:  2006-08-24       Impact factor: 4.296

4.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

5.  Obstetric aspects in women with facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and congenital myopathies.

Authors:  S Rudnik-Schöneborn; B Glauner; D Röhrig; K Zerres
Journal:  Arch Neurol       Date:  1997-07

Review 6.  The different roles of ER subtypes in cancer biology and therapy.

Authors:  Christoforos Thomas; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

7.  New Insights into Genotype-phenotype Correlations in Chinese Facioscapulohumeral Muscular Dystrophy: A Retrospective Analysis of 178 Patients.

Authors:  Feng Lin; Zhi-Qiang Wang; Min-Ting Lin; Shen-Xing Murong; Ning Wang
Journal:  Chin Med J (Engl)       Date:  2015-07-05       Impact factor: 2.628

8.  DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis.

Authors:  Paul Knopp; Yvonne D Krom; Christopher R S Banerji; Maryna Panamarova; Louise A Moyle; Bianca den Hamer; Silvère M van der Maarel; Peter S Zammit
Journal:  J Cell Sci       Date:  2016-10-15       Impact factor: 5.285

9.  Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation.

Authors:  Silvia Consalvi; Arianna Brancaccio; Alessandra Dall'Agnese; Pier Lorenzo Puri; Daniela Palacios
Journal:  Nat Commun       Date:  2017-01-09       Impact factor: 14.919

Review 10.  Facioscapulohumeral dystrophy: the path to consensus on pathophysiology.

Authors:  Rabi Tawil; Silvère M van der Maarel; Stephen J Tapscott
Journal:  Skelet Muscle       Date:  2014-06-10       Impact factor: 4.912

View more
  22 in total

1.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

2.  Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Authors:  Jonathan Oliva; Scott Galasinski; Amelia Richey; Amy E Campbell; Marvin J Meyers; Neal Modi; Jun Wen Zhong; Rabi Tawil; Stephen J Tapscott; Francis M Sverdrup
Journal:  J Pharmacol Exp Ther       Date:  2019-06-12       Impact factor: 4.030

3.  Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.

Authors:  Natalie K Katz; John Hogan; Ryan Delbango; Colin Cernik; Rabi Tawil; Jeffrey M Statland
Journal:  Brain       Date:  2021-12-16       Impact factor: 15.255

4.  Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?

Authors:  Lindsay N Alfano; Tahseen Mozaffar
Journal:  Brain       Date:  2021-12-16       Impact factor: 15.255

Review 5.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

6.  Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).

Authors:  Johanna Hamel; Nicholas Johnson; Rabi Tawil; William B Martens; Nuran Dilek; Michael P McDermott; Chad Heatwole
Journal:  Neurology       Date:  2019-08-13       Impact factor: 9.910

Review 7.  Promising Perspective to Facioscapulohumeral Muscular Dystrophy Treatment: Nutraceuticals and Phytochemicals.

Authors:  Ceren Hangül; Sibel Berker Karaüzüm; Esra Küpeli Akkol; Devrim Demir-Dora; Zafer Çetin; Eyüp İlker Saygılı; Gökhan Evcili; Eduardo Sobarzo-Sánchez
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

8.  Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.

Authors:  Ngoc Lu-Nguyen; Alberto Malerba; Shan Herath; George Dickson; Linda Popplewell
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

9.  Functional domains of the FSHD-associated DUX4 protein.

Authors:  Hiroaki Mitsuhashi; Satoshi Ishimaru; Sachiko Homma; Bryant Yu; Yuki Honma; Mary Lou Beermann; Jeffrey Boone Miller
Journal:  Biol Open       Date:  2018-04-26       Impact factor: 2.422

Review 10.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

Authors:  Anna Greco; Remko Goossens; Baziel van Engelen; Silvère M van der Maarel
Journal:  Clin Genet       Date:  2020-03-04       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.